Background
==========

Infection with *Mycobacterium tuberculosis*(M.*tb*), the causative agent of tuberculosis (TB), is one of the leading global health challenges \[[@B1],[@B2]\]. An estimated 8--10 million persons acquire tuberculosis annually, 2 million of whom die \[[@B1],[@B2]\]. The global TB epidemic has been complicated by the human immunodeficiency virus (HIV) co-epidemic \[[@B3]\]. Interaction between HIV and TB: (i) is associated with a higher risk of progression to active *M*. *tuberculosis*infection (ATBI) among persons with existing latent infection (LTBI); (ii) leads to increased susceptibility to new infection with M.*tb*; (iii) renders diagnosis difficult and treatment/cure rates slow; (iv) results in a higher incidence of relapses; and (v) favors the evolution of drug resistance \[[@B1],[@B4]-[@B6]\]. Amongst these, the emergence of drug resistance forms the deadliest challenge to controlling the TB epidemic. In HIV/TB high burden areas such as South Africa, drug resistance has extended from the first line anti-TB drugs to include the second line drugs spared for multi-drug resistant (MDR) TB, XDR \[[@B7]\]. Early detection of TB has a crucial role to play in controlling the epidemic here. In the past, diagnosis has been based on prediction of prior infection using the purified protein derivative (PPD)-tuberculin skin test (TST), detecting active TB by sputum smear staining using the Zeihl Neilson Stain (ZN) or culturing the organism on Lowenstein Jensen (LJ) medium; and radiographic imaging for TB-associated pathology \[[@B8],[@B9]\]. More recently, newer molecular assays for TB have emerged based on serology (detecting the 38 kDa antigen, Early Secretory Antigen or ESAT-6, CFP10 and other secretory antigens), nucleic acid amplification (NAATS), phage amplification and line probe assays for MDR \[[@B10]\]. Despite the advent of these modern TB assays, largely because there are no inexpensive technology platforms exploiting related biomarkers, approaches based on *in vitro*cultures still form the most reliable and readily affordable method for diagnosing TB in many resource-limited settings \[[@B10]\]. In general, *in vitro*culture of pathogens on appropriate growth media forms a \"pillar\" for both infectious disease diagnosis and drug sensitivity profiling \[[@B9]\].

Conventional cultures of the slowly-growing tubercle bacilli (M.*tb*) on LJ medium, though highly sensitive for TB \[[@B10]\], are nevertheless time-consuming since they take about two months to yield observable growth, thereby delaying disease diagnosis and appropriate intervention. Although reading of culture results is still widely based on physical observation of the formation of bacterial colonies, modified assays that predict changes in \'*in vitro*M.*tb*growth\" by monitoring turbidity or metabolism of labeled metabolites are occasionally used to confirm the presence of actively growing tubercle bacilli \[[@B9]-[@B13]\] and to characterize drug resistance \[[@B9],[@B14]-[@B16]\]. Specifically, some of these modified culture assays such as phage amplification assays, line probe assays and colorimetric redox-indicator methods can predict positive M.*tb*cultures (or drug resistance) in shorter times than the stipulated 2--3 months of culture on unmodified LJ medium. Most of these emerging TB assays are, however, still not readily available for routine use in most resource-limited settings where the TB burden is concurrently high \[[@B9]\]. We hypothesized that metabolomic-based assays of \"para-DNA duplicative\" changes during interphase could predict impending M.*tb*growth before actual growth occurs. Moreover, easier platforms such as chemilumniscence or fluorescence photodetection may be incorporated into these bioassays, thereby making them more affordable than the aforementioned existing methods for TB detection \[[@B10]\]. That hypothesis is derived from and based on several biological principles of the cell cycle, which are discussed below.

**First**, prokaryotic growth and proliferation, unlike that of eukaryotes, is predominantly achieved through division of single cells \[[@B17]\]. The period between the \"birth\" of two daughter cells from the parent cell and their own division is termed interphase. During interphase, cells undergo a resting (S) phase during which, though little physical activity is noted microscopically, DNA duplication occurs \[[@B17]\]. Since DNA synthesis precedes actual microbial division and proliferation, monitoring \"DNA synthesis\" may predict microbial growth changes well before the visible manifestation of actual microbial growth in culture.

**Second**, phosphorylation of deoxythymidine monophosphate (dTMP) is a critical step in the pathway leading to the synthesis of thymidylate triphosphate (TTP), a necessary precursor for DNA synthesis \[[@B18]\]. This process is catalyzed by enzymes called kinases or phosphotransferases \[[@B18]\]. Among mammalian cells, two phosphotransferases exist: thymidine kinases (types 1 and 2) and thymidylate kinase \[[@B18]\]. Sherley and Kelly have previously reported a positive correlation between levels of human TK and DNA duplicative changes in the cell cycle \[[@B19]\]. Within mycobacterial proteomes, however, no thymidine kinase has been detected \[[@B18]\]. Instead, mycobacterial thymidylate kinase (TMKmyc) carries out this critical phosphorylative function \[[@B18]\]. From this knowledge base, we proposed that levels of TMKmyc may similarly parallel DNA synthesis during the M.*tb*cell cycle \[[@B18],[@B19]\]. We recently focused on research and development of an antibody-based biomarker for TMKmyc. To date, we have identified highly conserved surface linear peptides of TMKmyc as potential B-cell immunogens for *in situ*engineering of TMK-specific monoclonal antibodies (MAbs). Such TMKmyc-specific MAb(s) could be used to monitor of levels of TMKmyc in cultures of M.*tb*. In this paper, we attempt to provide a theoretical framework upon which we propose **reduction of time-lines for positive identification and drug resistance profiling among *Mycobacterium tuberculosis*(M. *tb*) cultures using thymidylate kinase (TMK) assays**.

Methods and results
===================

1. Arithmetical derivations of the systems biology of the tubercle bacillus growth curve
----------------------------------------------------------------------------------------

### (a) Theoretical partition of the tubercle bacillus cell cycle

We partitioned a \"model\" cell cycle of the tubercle bacillus, according each phase (G~1~, S, G~2~and M) a time line \[[@B17]\]. These still ambiguous times have been designated: **t**~**s**~= time taken by the parent cell in the S phase; **t**~**(s+G2)**~= time taken for completion of a single \'cycle of the central dogma\', i.e from DNA synthesis to protein expression; and **t**~**(G1+s+G2)**~= generation time of a tubercle bacillus (see Fig. [1](#F1){ref-type="fig"}). These are likely to vary from one cell type to another.

![**The tubercle bacillus cell cycle**. The figure offers a graphic illustration of the cell cycle of the tubercle bacillus partitioned into the S (stationery or synthetic), G and M (mitotic) phases. Note that the times **t~**s**~**, **t**~**(s+G2)**~**and t**~**(G1+s+G2)**~are in a practical sense unknown.](1742-4682-6-4-1){#F1}

### (b) Tubercle bacillus growth curve patterns and biometric algorithms

As for all microbes, we assumed that the growth of tubercle bacilli follows the same \"S\" pattern, characterized by an initial \"slow growth\" phase, then an exponential phase and finally a stationary stage. The arithmetic of \"S\" curves is largely quadratic, the relationship between number of colonies per unit (μ) at any time (t) being stated as a derivative of the equation μ = at^2^+ bt + c (see Fig. [2](#F2){ref-type="fig"}). From this equation, we infer that the constants c, b and a respectively represent: c = the number of viable cells in the initial inoculum; b = the number of actively growing cells during the slow growth phase; and a = the cell division (or turnover) rate during exponential phase.

![**A theorized tubercle bacillus growth curve (colonies per unit against time in months)**. The figure shows the typical S pattern characteristic of the growth of microbes in culture. Note the existence of an initial slow growth phase, followed by an exponential stage and finally a stationary phase.](1742-4682-6-4-2){#F2}

2. Geometric correlation of TMKmyc levels with the M.*tb*growth curve
---------------------------------------------------------------------

We employed systems and chemical biology models to parallel \"M.*tb*growth curves\" theoretically with \"TMKmyc curves\" in four different scenarios. **First**, we assumed that the level of TMKmyc within an M.*tb*culture is equal to the total TMKmyc produced by all the functionally viable cellular units within all the colonies *in vitro*. This assumption was aimed at minimizing the impact of heterogeneity within the culture, which may contain an admixture (quasi) of dividing and non-dividing M.*tb*. Basically, as long as overall proliferation occurs, the cumulative levels of TMK would rise in proportion. **Second**, assuming that DNA synthesis occurs 2, 4, 6 and 8 days after inoculation (and that these are the equivalent time-lines for the G~1~phase, t~G1~); then a further 58, 56, 54 and 52 days would be required for actual division of the tubercle bacilli to occur. Therefore, M.*tb*DNA synthesis may parallel the actual growth of tubercle bacilli but occur at a much earlier time. Hence the total secreted levels of enzymes such as TMKmyc synthesized during the cell cycle may parallel the \"S\" pattern of the microbial growth curve (and equally obey the quadratic equation); except that these changes are bound to occur much earlier.

Overall, assuming that the cumulative levels of tmk in the culture is the total tmk derived from the individual cells in the culture, then, as for the microbial growth curves, it is highly probable that TMKmyc levels will obey an \"S\" pattern consistent with quadratic equations, but one that is manifest earlier. The levels of tmk per unit (\|tmk\|) at any time (t) on this gradient may therefore be represented as the product of the equation \|tmk\| = at^2^+ bt + c, where a, b and c are constants (possibly representing: a = multiple of the levels of TMPKmyc required to salvage a mole of dTMP during the exponential phase of M.*tb*growth; b = factor of levels of TMKmyc required to phosphorylate dTMP during the initial slow growth phase; and c = level of tmk required to phosphorylate a single dTMP molecule within the initial inoculum when no active division is ongoing) (see Fig. [3](#F3){ref-type="fig"}).

![**Predicted pattern of TMKmyc variation in M.tb cultures**. This figure aims to illustrate the predicted pattern of variation in TMKmyc levels with the cell cycle, assuming that (1) levels of TMKmyc parallel growth changes and (2) DNA synthesis occurs 2--6 days after inoculation of the sample on LJ medium.](1742-4682-6-4-3){#F3}

3. Prediction of drug sensitivity profiles based on TMKmyc levels rather than observation of M.*tb*growth changes (colonies per unit)
-------------------------------------------------------------------------------------------------------------------------------------

Two drug resistance profiling scenarios were modelled, isoniazid (INH) resistance and sensitivity. In the INH resistance scenario, we projected that although the dose of INH in LJ is optimal for stopping M.*tb*proliferation, tubercle bacilli will continue to grow. Because the time-line for observing these growth changes (colonies/unit) is long, we believe that predictions of such growth changes based on TMKmyc assays (which parallel growth changes but occur earlier) may be a relatively quick way of determining drug resistance. In the INH sensitive scenario, since the drug inhibits or slows microbial growth, these changes may equally be predicted by TMKmyc levels recorded in the presence of the drug (growth is bound to be absent or at least much lower than in the absence of drug or in the drug resistance scenario) (see Fig. [4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"} for illustrations of INH sensitive and resistant scenarios respectively).

![**Projected patterns of variation of TMKmyc curves in the drug sensitive and resistance scenario against a normal TMKmyc curve**. This figure shows theorized patterns of variation for TMKmyc curves in the drug sensitive (A) and resistance (B) scenarios against a background normal TMKmyc curve. Note that, from this illustration, one could say that the extent of resistance (or number of mutant phenotypes) present in scenario B is the difference between the areas under both curves shaded light yellow. Note also that for any drug resistance profiling based on tmk assays, resistance may be viewed as inversely correlated to TMKmyc levels, while sensitivity is directly proportional to levels of TMK. The difference between TMKmyc levels of test versus standard TMKmyc curve is denoted by a window \"wj\" or wayengera-joloba lag, the numerical value of which is \"WJ\". Overall, drug sensitivity \~WJ and resistance \~1/WJ.](1742-4682-6-4-4){#F4}

Discussion
==========

This paper provides the first ever theoretical and modeling framework to support the view that assays of enzymes involved in the synthesis of DNA precursors may be applied to shorten the time-lines to positive identification of microbial cultures (and possibly of other cell lines including cancers). Specifically: if variations in TMKmyc during the S phase of the tubercle bacillus cell cycle are independent of the time taken by the tubercle in other stages of the cycle, then TMKmyc assays are a potential predictive biomarker of *in vitro*M.*tb*growth that may be applied to reducing the time-lines to positive identification of *Mycobacterium tuberculosis*(M.*tb*) cultures. There are several existing methods for detecting TB within cultures, but they mostly lack inexpensive platforms for routine use within resource-limited settings where the TB burden is highest \[[@B10]\]. Moreover, many of these emerging TB assays \[[@B10]\] are not specific for detecting duplicative changes in M.*tb*DNA. We therefore felt it necessary to establish a highly specific M.*tb*DNA duplicative assay that may be mounted on inexpensive technology platforms that are currently widely used within resource-limited settings, such as lateral flow immunochromatography.

Overall, tmk-based assays are therefore likely to be cheap but still serve the purpose of accelerating diagnosis and drug resistance profiling of M.*tb*and possibly other infectious diseases in culture. **First**, we show here why variations in the durations of the G~1~, S and G~2~phases of the M.*tb*cell cycle may account for a longer \'culture time\' for M.*tb*(see Fig. [1](#F1){ref-type="fig"} for illustration) than for other microbes. In principle, the generation time of any cell is determined by the time it spends in G~1~and G~2~\[[@B17]\]. Some cells, however, are known to go into deeper states of latency or dormancy (designated G~0~or even G~00~), only reverting to the G~1~stage when a need for reproduction, proliferation or regeneration arises \[[@B17]\]. Various environmental factors are known to initiate such deeper states of dormancy in microbes and eukaryotes alike including low temperature, absence of nutrients and low oxygenation states \[[@B20]\]; though the full range of factors that determine why tubercle bacilli go into related states of latency *in vivo*are yet to be fully established \[[@B1],[@B21]\]. It is therefore unclear whether these deeper states of dormancy explain the slowly-growing nature of M.*tb*(especially since host immune factors also seem to play a significant role in arresting M.*tb*proliferation *in vivo*\[[@B21]\]). What is evident from our theoretical models, though, is that experiments aimed at establishing the actual values of the durations t~G1~, t~s~and t~G2~for various microbes including M.*tb*may yield significant knowledge about the rate-limiting steps in their \"growth\" activity when cultured. For instance, using our proposed TMKmyc antigen capture assays, together with radio-labeled phosphorylated (dTMP^*r*^) nucleotide bases as metabolites, the time t~s~required for DNA duplication by the tubercle bacillus may be estimated.

**Second**, from the theoretical model that the timeline for the G~1~phase of the M.*tb*cell cycle (t~G1~) is constant at 2, 4, 6 or 8 days, we inferred a parallel correlation of tubercle bacillus \"growth changes\" with TMK levels in each scenario (although changes in TMKmyc levels were predicted to occur much earlier, as noted in Figure [3B](#F3){ref-type="fig"}). These predictions are based on the hypothesis that since DNA synthesis precedes all cellular division, and TMKmyc is required to create the dTTP necessary for DNA synthesis, monitoring the levels of TMKmyc may predict actual growth changes well before such changes occur. Note, however, that the actual durations of the constituent phases of the M.*tb*cell cycle remain uncertain as stated above. One may therefore be justified in arguing that this presumption regarding the timing of the G~1~phase of the M.*tb*cell cycle at days 2, 4,\.... etc. is currently speculative, given that it is not yet clear which of the two stages, G~1~or G~2~, constitutes the larger proportion of the generation time of the tubercle bacillus (see Fig. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Nevertheless, using this arbitrary presumption that DNA synthesis may occur only days after inoculation and that it is the G~2~phase rather than G~1~that accounts for much of the delay in physical manifestation of M.*tb*growth changes in culture, we show here that TMKmyc assays could predict TB growth *in vitro*as early as day 2 of culture. Moreover, we have successfully used it here to theorize that TMKmyc assays may also be exploited to distinguish drug-sensitive from -- resistant forms of tuberculosis in culture (see Fig. [4](#F4){ref-type="fig"}). In this context, those test samples with evident rises in TMKmyc levels would in a practical sense be resistant to the drug being tested, whereas isolates where TMKmyc levels fail to rise are sensitive. **From the graphs 4 A and B**, one equally notes that: (1) tubercle bacillus drug sensitivity is an inverse factor of TMKmyc while existing resistance profiles are directly correlated to TMKmyc levels; (2) by measuring and quantifying the comparative difference between the areas under the TMKmyc curves (AUC) of resistant and sensitive isolates, it may be possible to quantify the existing levels of resistance (or number of resistant mutants). Assuming that the difference between TMKmyc levels in stationary phase between the tested M.*tb*isolates and the standard tmk curve is arbitrarily denoted a window \"wj\" of which the numerical value is \"WJ\"; then:

Note that in equations I and II representing tmk variation in sensitive and resistant M.*tb*isolate scenarios respectively; the \|tmk\| levels within the test isolate culture are inversely correlated to the numerical value of the wayengera-joloba lag or \"wj\" window, also denoted \"WJ\".

The above Area Under Curve (AUC) method for drug resistance profiling offers a means of quantifying drug resistance. Such ability to quantify resistance is especially clinically significant within resource-limited settings where second-line TB chemotherapy options are limited and drugs with minimal evident resistance are useful in combination with other drugs to which the isolate being treated is not resistant. In other words, TMK assays would enable the derivation of \"salvage\" regimens from the limited available drug options. Supposing that tmk levels follow a quadratic curve as above, parallel to the \"S\" growth curve of microbes, then this AUC can be calculated as the integral (∫) of the equation: \|tmk\| = at^2^+ bt + c or simply 1/3 at^3^+1/2 bt^2^+ct. From this equation, it can also be derived that the drug sensitivity of tubercle bacilli is an inverse factor of the AUC while existing resistance profiles are directly correlated to the same Area. However, in order to compare the prevailing resistance profiles between two isolates, one would need first to define the time over which to make the above calculations (say t~1~-t~2~); although we recommend that future universal algorithms be based on the AUC between t = 0 and the t-value when the tmk levels first reach the stationery stage. Note also that TMKmyc assays have the advantage of being applicable to all drug scenarios without the need for modifications such as those required for colorimetric redox-indicator methods or nitrate reductase assays, which have been found to be highly sensitive only for rifampicin and isoniazid resistance testing \[[@B9]\]. Moreover, targeted detection of other related microbial enzymes such as HIV thymidine kinase may enable drug resistance profiling for HAART to be conducted within resource-limited settings, where inexpensive platforms for phenotyping or genotyping for drug sensitivity have remained mostly lacking \[[@B22]\]. In the case of the M.*tb*scenario, whether or not the proposed TMKmyc-based drug profiling assay would yield consistent results relative to several existing rapid drug resistance tests such as phage amplification, or line probe assays such as INNO-LipA Rif.TB(LiPA) or Genotype MTBDR, is a subject that requires future comparative evaluations once TMKmyc assays are in practical use \[[@B9]\].

Several limitations are evident in our theoretical model, which must be dealt with prior to the actualization of TMKmyc assays as a predictive biomarker for *in vitro*tubercle bacillus growth. **First**, it is currently unclear whether secreted TMKmyc is present in the culture medium at levels detectable by MAb(s). Specifically, existing data provide contradictory views about the possible secretory nature of TMKmyc. Munier-Lehmman et al. \[[@B18]\] have previously shown that TMKmt forms over 30% of all colony filtrate proteins in a strain of *E*. *coli*genetically engineered to express TMKmt. However, other studies on host sera using *in vivo*-induced antigen technology (IVIAT) \[[@B23]-[@B25]\] and crossed immunoelectrophoresis (CIE) \[[@B26]\], though identifying over 11 genes involved in M.*tb*metabolism, do not categorically list TMKmt among them. Note, however, that the absence to date of methods for specific monitoring of TMKmyc (such as the one we propose) among the latter studies \[\[[@B23]-[@B25]\] and \[[@B26]\]\] relative to work by Munier-Lehmann and colleagues \[[@B18]\] may possibly explain these discrepancies. **Second**, it is assumed that TB cultures constitute a homogenous mixture of actively proliferating cells. Within wild type M.*tb*cultures, however, this may not be the case as active and dormant tubercle may co-exist. Such heterogeneity of growth among the M.*tb*in culture may also affect TMKmyc secretory levels. We hold that since qualitative rather than quantitative measures of TMKmyc are required to determine M.*tb*culture positivity, TMKmyc-based assays are still valid for the purpose of reducing time-lines to the reading of TB cultures. What may be affected is drug resistance profiling, since this requires measurement of the levels of TMK in the culture. Therefore, for purposes of drug resistance profiling, more algorithms may need to be integrated into the TMKmyc assays to render them more standardized and reliable in the face of heterogeneity of M.*tb*proliferation *in vitro*. **Third**, in the absence of *in vitro*evidence to support the view that TMKmyc may be adequately and specifically detected by monoclonal antibodies, the proposed assays for TMKmyc levels in culture are still speculative. Whether TMKmyc-based assays will perform better than, worse than or the same as existing TB tests \[[@B10]\] therefore remains elusive and requires future comparative clinical trials. More work needs to be done to affirm the binding affinity and specificity of the antigen capture assays for TMKmt. This work is, however, complicated by the findings by Steingart and colleagues, who recently reported inconsistencies in most commercially available TB serodiagnostics \[[@B16]\]. **Fourth**, although it is clear that DNA duplication precedes actual microbial division \[[@B17]\], the duration of this process among various microbes including M.*tb*is largely unclear. Studies such as that by Sherley and Kelly \[[@B19]\] are therefore needed for M.*tb*and other infectious pathogens alike. Overall, if the above-listed potential shortcomings are overcome, the proposed antibody-based TMKmyc assays provide the flexibility to be mounted on a cheap technology platform for use within resource-limited settings. For instance, incorporation of \"chemiluminiscent or fluorescent\" strategies may enable \"photo-detection of TMKmyc changes in culture\" and thereby automation of the entire assay. Specifically, if the initiation of light emission is tailored to antigen (TMKmyc) capture, then chemiluminiscent or fluorescent TMKmyc-specific antibodies (CAbs and FAbs respectively) may be integrated within the LJ medium so that visual observation of color change or photometric measurements may be used to detect the levels of TMKmyc secreted. This simple automation could remove the need to conduct laborious quantitative ELISA or antigen capture assays to monitor TMKmyc levels, and thereby allow use by persons without extensive specialized training. Lastly, as TMKmyc is a specific antigen of M.*tb*\[[@B18]\], targeted detection of TMKmyc in sputum may provide an alternative strategy for diagnosing symptomatic TB to that based on staining for AFBs.

Conclusion
==========

TMKmyc assays may be applicable to reducing time-lines to determining positivity of *Mycobacterium tuberculosis*(M.tb). Moreover, TMKmyc assays may also serve to hasten drug resistance profiling *in vitro*. The inherent flexibility of the proposed antigen capture assay allows the potential incorporation of simple technologies such as chemiluminiscent or fluorescent strategies and could enable easy-to-use platforms to be built such as those based on \"photo-detection of TMKmyc changes in culture\", as well as automation of the entire assay.
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